



SOCIETY FOR
TRANSLATIONAL
ONCOLOGY®



MASSACHUSETTS
GENERAL HOSPITAL
CANCER CENTER

2017 Chabner Colloquium: *Answering the Big Questions in Cancer Research*

The Liberty Hotel – Boston, MA

Monday, October 30, 2017

AGENDA

7:00 a.m. Registration Opens

7:45 a.m. Welcome and Introductions

Session 1: New Insights into DNA Repair and Drug Response

8:00 a.m.	Alan D'Andrea, MD Dana-Farber Cancer Institute	Exploiting Repair Pathways Mutated in Cancer
8:45 a.m.	Ted Hong, MD MGH Cancer Center	Assessing DNA Repair in Clinical Trials
9:30 a.m.	Karen Cichowski, PhD Harvard Medical School	K-RAS Pathway as a Target for Cancer Treatment
10:15 a.m.	Lee Zou, PhD MGH Cancer Center	Roles for Inhibition of ATR/ATM in Cancer Therapy

11:00 – 11:15 a.m. Break/Exhibits

Session 2: Targets That Defy Effective Therapy

11:15 a.m.	Lipika Goyal, MD MGH Cancer Center	Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?
12:00 p.m.	Leif Ellisen, MD, PhD MGH Cancer Center	Evidence for Translocations as Major Genetic Lesions in Breast Cancer

12:45 p.m. – 1:30 p.m. Lunch Buffet and Exhibits

Session 3: Promising Drug-Antibody Conjugates and Cell Death Pathway Inhibitors

1:30 p.m.	Anna Farago, MD, PhD MGH Cancer Center	Rovalpituzumab for Small Cell Cancers
2:15 p.m.	Aditya Bardia, MD, MPH MGH Cancer Center	Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative
3:00 p.m.	Steven J. Isakoff, MD, PhD MGH Cancer Center	PARP in Breast Cancer

3:45 p.m. – 4:00 p.m. Break/Exhibits

Session 4: Junior Faculty Forum

4:00 p.m.	Russ Jenkins, MD Dana-Farber Cancer Institute	RAS-targeted Drug Development
4:30 p.m.	Zofia Piotrowska, MD MGH Cancer Center	Improving EGFR Therapy
5:00 p.m.	Ryan Nipp, MD, MPH MGH Cancer Center	Financial Toxicity of Cancer

5:30 p.m. Closing Remarks / Adjournment